Deltex Medical Group PLC Annual Report and Notification of AGM (3458O)
17 May 2018 - 4:01PM
UK Regulatory
TIDMDEMG
RNS Number : 3458O
Deltex Medical Group PLC
17 May 2018
17 May 2018
Deltex Medical Group plc
("Deltex" or "the Company")
Publication of Annual Report and Notification of AGM
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), gives notice that its
Annual Report and Accounts for the year ended 31 December 2017
("Annual Report & Accounts 2017") has been published on the
"Annual & Interim Reports" section of the Company's website at
www.deltexmedical.com.
The Company announced a summary of its results on 9 May 2018 and
expects to post printed copies of the Annual Report & Accounts
2017 on 23 May 2018 to shareholders who have informed the Company
of their wish to receive reports of this nature in hard copy.
Deltex also announces that its Annual General Meeting will be
held at 11:00am on 20 June 2017 at the offices of DAC Beachcroft
LLP, 100 Fetter Lane, London EC4A 1BN. The formal notice and
resolutions can be found at the back of the Annual Report &
Accounts 2017. The related proxy card is expected to be posted on
23 May 2018 to shareholders on the register on 11 May 2018.
For further information, please contact:-
Deltex Medical Group plc 01243 774 837
investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Jonathan Shaw, Group Finance
Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments (TPI) 0203 621 4120
Ltd info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory Ltd 0203 934 6630
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM (TrueVue(TM)
Doppler) is the only technology to measure blood flow in the
central circulation in real time. Minimally invasive, easy to set
up and quick to focus, the technology generates a low-frequency
ultrasound signal, which is highly sensitive to changes in flow and
measures them immediately. Deltex has been the only Group in the
enhanced haemodynamic space to build a robust and credible evidence
base proving the clinical and economic benefits of its core
technology, TrueVue(TM) Doppler which is proven to reduce
complications suffered by patients after surgery and save hospitals
the costs of treating those complications.
Deltex Medical's TrueVue(TM) System on the CardioQ-ODM+ monitor
platform also now provides clinicians with two further advanced
haemodynamic monitoring technologies. High Definition Impedance
Cardiography is an entirely non-invasive monitoring technology
which creates an electrical field across the chest and measures the
disruption to this field when the heart pumps blood. Pulse Pressure
Waveform Analysis uses peripheral blood pressure signal analysis to
give doctors information on changes in the circulation and is
particularly suited to monitoring lower risk or haemodynamically
stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Group's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Group aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Group to partner
healthcare providers to support modern haemodynamic management
across the whole hospital.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOADQLFFVEFBBBK
(END) Dow Jones Newswires
May 17, 2018 02:01 ET (06:01 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024